Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of TAS-116 on cardiovascular safety in advanced solid tumors
jRCT2080224077Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Nonhematologic neoplasms comparing TAS-116 with Placebo (2 arms). Primary endpoint: Cardiovascular safety (QTcF interval). Started Oct 2018; status: completed.
02
Drugs
pimitespib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224077.